Welcome

Superbugs Win Another Round as Big Pharma Leaves Antibiotics (1)

July 13, 2018, 12:35 PM

The fight against life-threatening infections suffered another blow when one of the world’s biggest drugmakers waved the white flag.

Novartis AG is the latest drug giant to end antibacterial and antiviral research, joining the likes of AstraZeneca Plc, Sanofi, Allergan Plc and Medicines Co.GlaxoSmithKline Plc has put some antibiotics assets under review.

The pullback revives concern about a world in which routine infections again become lethal as bugs develop resistance to existing drugs. Sales of new antibiotics are too low for big pharma to recoup its investments, and public measures to encourage more activity aren’t moving the needle.

“The market ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.